GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » Cyclically Adjusted PB Ratio

Phio Pharmaceuticals (FRA:44R3) Cyclically Adjusted PB Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Phio Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Phio Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 - - -

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Phio Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Phio Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Phio Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Phio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Phio Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.235/131.7762*131.7762
=2.235

Current CPI (Mar. 2024) = 131.7762.

Phio Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 7,413.636 100.560 9,715.052
201409 6,975.000 100.428 9,152.237
201412 2,866.667 99.070 3,813.058
201503 4,929.787 99.621 6,520.994
201506 11,938.776 100.684 15,625.602
201509 10,030.612 100.392 13,166.413
201512 8,243.434 99.792 10,885.482
201603 6,307.071 100.470 8,272.306
201606 4,466.667 101.688 5,788.292
201609 2,705.000 101.861 3,499.422
201612 3,527.411 101.863 4,563.288
201703 2,308.683 102.862 2,957.641
201706 1,501.136 103.349 1,914.037
201709 801.671 104.136 1,014.458
201712 420.924 104.011 533.287
201803 112.469 105.290 140.762
201806 423.752 106.317 525.227
201809 222.552 106.507 275.354
201812 418.039 105.998 519.705
201903 291.225 107.251 357.821
201906 225.960 108.070 275.528
201909 177.643 108.329 216.092
201912 92.723 108.420 112.698
202003 45.383 108.902 54.916
202006 32.692 108.767 39.608
202009 27.236 109.815 32.683
202012 22.211 109.897 26.633
202103 23.386 111.754 27.576
202106 21.227 114.631 24.402
202109 19.026 115.734 21.663
202112 17.209 117.630 19.279
202203 15.517 121.301 16.857
202206 14.132 125.017 14.896
202209 11.995 125.227 12.622
202212 8.982 125.222 9.452
202303 5.934 127.348 6.140
202306 4.605 128.729 4.714
202309 2.929 129.860 2.972
202312 3.072 129.419 3.128
202403 2.235 131.776 2.235

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Phio Pharmaceuticals  (FRA:44R3) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Phio Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (FRA:44R3) Business Description

Traded in Other Exchanges
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Phio Pharmaceuticals (FRA:44R3) Headlines

No Headlines